Rakesh Kumar

13PUBLICATIONS
148CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsPredictive and prognostic markersAerospace materials
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.

Tina Cascone, Laura Bonanno, Florian Guisier

|May 12, 2025
First-in-Human Study to Evaluate the Safety and Efficacy of Anti-GDF15 Antibody AZD8853 in Patients with Advanced/Metastatic Solid Tumors.

Benedito A Carneiro, Olumide B Gbolahan, Albiruni Abdul Abdul Razak

|Mar 29, 2025
Quantifying CD73 expression after chemotherapy or chemoradiotherapy in esophageal squamous cell carcinoma.

Zachary A Cooper, Ying Wang, Philip L Martin

|Aug 06, 2024
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Andrew L Coveler, Matthew J Reilley, Mark Zalupski

|Jul 24, 2024
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer.

Neil H Segal, Jeanne Tie, Scott Kopetz

|Feb 13, 2024
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.

Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park

Pageof 3

Frequent Collaborators

5 joint publications

Zachary A Cooper

3 joint publications

Dong-Wan Kim

3 joint publications

Patrick M Forde

3 joint publications

Charu Aggarwal